These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
371 related articles for article (PubMed ID: 31831042)
1. Prognostic impact of pathological complete remission after preoperative irradiation in patients with locally advanced head and neck squamous cell carcinoma: re-analysis of a phase 3 clinical study. Wang K; Yi J; Huang X; Qu Y; Luo J; Xiao J; Zhang S; Tang Y; Liu W; Xu G; Gao L; Xu Z; Liu S; Wang X Radiat Oncol; 2019 Dec; 14(1):225. PubMed ID: 31831042 [TBL] [Abstract][Full Text] [Related]
2. Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma. Yi J; Huang X; Xu Z; Liu S; Wang X; He X; Luo D; Luo J; Xiao J; Zhang S; Wang K; Qu Y; Tang Y; Liu W; Xu G; Gao L; Wang D Oncotarget; 2017 Jul; 8(27):44842-44850. PubMed ID: 28179586 [TBL] [Abstract][Full Text] [Related]
3. Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis. Mohamed A; Twardy B; Zordok MA; Ashraf K; Alkhoder A; Schrapp K; Steuer C; Chen Z; Pakkala S; Pillai R; Trad Wadsworth J; Higgins K; Beitler JJ; Ramalingam SS; Owonikoko TK; Khuri FR; Shin DM; Behera M; Saba NF Head Neck; 2019 May; 41(5):1490-1498. PubMed ID: 30835900 [TBL] [Abstract][Full Text] [Related]
4. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Giralt J; Trigo J; Nuyts S; Ozsahin M; Skladowski K; Hatoum G; Daisne JF; Yunes Ancona AC; Cmelak A; Mesía R; Zhang A; Oliner KS; VanderWalde A Lancet Oncol; 2015 Feb; 16(2):221-32. PubMed ID: 25596659 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma. Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535 [TBL] [Abstract][Full Text] [Related]
6. Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis. Tang WH; Sun W; Long GX Medicine (Baltimore); 2020 Sep; 99(36):e21785. PubMed ID: 32899005 [TBL] [Abstract][Full Text] [Related]
7. Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer". Schüttrumpf L; Marschner S; Scheu K; Hess J; Rietzler S; Walch A; Baumeister P; Kirchner T; Ganswindt U; Zitzelsberger H; Belka C; Maihoefer C Radiat Oncol; 2020 Jan; 15(1):7. PubMed ID: 31906998 [TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials. Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131 [TBL] [Abstract][Full Text] [Related]
9. Survival outcomes for head and neck cancer patients with N3 cervical nodal metastases. Virk JS; Ingle M; Podesta CM; Gujral DM; Awad Z Clin Otolaryngol; 2020 May; 45(3):342-349. PubMed ID: 31869000 [TBL] [Abstract][Full Text] [Related]
10. Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly? Haehl E; Rühle A; David H; Kalckreuth T; Sprave T; Stoian R; Becker C; Knopf A; Grosu AL; Nicolay NH Radiat Oncol; 2020 Feb; 15(1):31. PubMed ID: 32019576 [TBL] [Abstract][Full Text] [Related]
11. Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94). Ghadjar P; Pöttgen C; Joos D; Hayoz S; Baumann M; Bodis S; Budach W; Studer G; Stromberger C; Zimmermann F; Kaul D; Plasswilm L; Olze H; Bernier J; Wust P; Aebersold DM; Budach V Strahlenther Onkol; 2016 Aug; 192(8):552-60. PubMed ID: 27323753 [TBL] [Abstract][Full Text] [Related]
12. Outcomes in N3 Head and Neck Squamous Cell Carcinoma and Role of Upfront Neck Dissection. Boros A; Blanchard P; Dade A; Gorphe P; Breuskin I; Even C; Nguyen F; Deutsch E; Bidault F; Janot F; Temam S; Mirghani H; Tao Y Laryngoscope; 2021 Mar; 131(3):E846-E850. PubMed ID: 32833260 [TBL] [Abstract][Full Text] [Related]
13. Accelerated Radiotherapy with Concurrent Chemotherapy in Locally Advanced Head and Neck Cancers: Evaluation of Response and Compliance. Mashhour K; Atef H; Selim A; A Moez M; Zawam H; Abo-Madyan Y Asian Pac J Cancer Prev; 2020 May; 21(5):1399-1407. PubMed ID: 32458648 [TBL] [Abstract][Full Text] [Related]
14. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer. Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976 [TBL] [Abstract][Full Text] [Related]
15. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844 [TBL] [Abstract][Full Text] [Related]
16. The change in circulating tumor cells before and during concurrent chemoradiotherapy is associated with survival in patients with locally advanced head and neck cancer. Wang HM; Wu MH; Chang PH; Lin HC; Liao CD; Wu SM; Hung TM; Lin CY; Chang TC; Tzu-Tsen Y; Hsieh JC Head Neck; 2019 Aug; 41(8):2676-2687. PubMed ID: 30903634 [TBL] [Abstract][Full Text] [Related]
17. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy. Strongin A; Yovino S; Taylor R; Wolf J; Cullen K; Zimrin A; Strome S; Regine W; Suntharalingam M Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1823-30. PubMed ID: 21549516 [TBL] [Abstract][Full Text] [Related]
18. Lymph node ratio as a prognostic factor for survival in patients with head and neck squamous cell carcinoma. Sano D; Yabuki K; Takahashi H; Arai Y; Chiba Y; Tanabe T; Nishimura G; Oridate N Auris Nasus Larynx; 2018 Aug; 45(4):846-853. PubMed ID: 29203318 [TBL] [Abstract][Full Text] [Related]
19. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Mesía R; Henke M; Fortin A; Minn H; Yunes Ancona AC; Cmelak A; Markowitz AB; Hotte SJ; Singh S; Chan AT; Merlano MC; Skladowski K; Zhang A; Oliner KS; VanderWalde A; Giralt J Lancet Oncol; 2015 Feb; 16(2):208-20. PubMed ID: 25596660 [TBL] [Abstract][Full Text] [Related]
20. High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer. Chang CL; Yuan KS; Wu SY Head Neck; 2017 Jul; 39(7):1364-1370. PubMed ID: 28370614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]